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OBJECTIVES: To develop a symptom-based outcome
measure for asthma by measuring patient preferences
over asthma symptoms. METHODS: Asthma patients
were asked to choose between scenario pairs where each
scenario described the patient’s asthma symptoms over a
period of one week. Their responses to a series of such
choices were modelled using a random effects ordered
probit model. The particular symptoms considered were
daytime cough, daytime chest tightness, daytime wheeze,
daytime breathlessness, and sleep disturbance as a result
of night-time asthma symptoms. Questionnaires contain-
ing eight discrete choices were completed by 162 moder-
ate to severe asthma patients. RESULTS: The hypothesis
that patients weight the five symptoms equally was
clearly rejected. Specifically, daytime cough and breath-
lessness were weighted twice as heavily as the other three
symptoms. The weights did not appear to be influenced
by the patient’s age, gender, or asthma severity. There
was no evidence that the order in which symptoms were
presented affected the results. However, there was some
evidence that the conventional linear additive model may
not be suitable. CONCLUSIONS: Discrete choice model-
ling proved to be a useful approach for developing pref-
erence based outcome measures. There is considerable
scope and need for further refinement of the methods.
While the specific application reported concerned asthma
symptoms the general approach is potentially useful in a
wide range of applications.
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OBJECTIVES: Quality of life, lung function values, and
disease severity classification systems are frequently used
in clinical practice, clinical trials and in economic evalua-
tion of asthma treatment. However, the relationship
among these measurements is not well understood yet.
The objective of this study was to identify quality of life
values of asthmatic patients with different severity of dis-
ease based on the GINA severity classification system. To
examine the correlation between lung function values
(FEV1, PEF) and generic and disease-specific QoL mea-
surements. METHODS: 228 consecutive adult outpa-
tients and inpatients at four sites participated in the
study. Doctors had to classify the severity of disease and
report the latest measured FEV1 and PEF values. Patients
had to fill in three different quality of life questionnaires.
RESULTS: Mean quality of life values were 21, 38, 52,
60 for SGRQ questionnaire; 48, 43, 36, 31 for SF-36
(PCS); 55, 46, 42, 44 for SF-36 (MCS); 0.93, 0.76, 0.65,
0.52 for EuroQol weighted health status in the four se-
verity groups, respectively. Correlation coefficients were
0.62 between EuroQol and PCS; 0.59 between EuroQol
and MCS; 0.74 between SGRQ and PCS; 0.58 be-
tween SGRQ and MCS; 0.68 between SGRQ and Eu-
roQol. Correlation was 0.28, 0.37, 0.01, 0.21 be-
tween FEV1% and SGRQ, PCS, MCS, and EuroQol,
respectively. Similar values were gained in the case of
PEF% values. CONCLUSIONS: Lung function and QoL
values correlated less than medium strongly while differ-
ent QoL values correlated to each other stronger than
medium. Large differences were detected in QoL accord-
ing to disease severity. These results can be of high value
in modeling and burden of disease studies.
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OBJECTIVE: Prediction of future need for healthcare is
an essential component of pharmacoeconomic models.
However, recent developments in applied econometrics
have demonstrated the importance of investigating for
heterogeneity of risk within populations when using
count data (e.g. hospitalization). We tested the hypothe-
sis that there is a healthy sub-population with very low
risk of hospitalization amongst patients with Type 2 dia-
betes. METHODS: The study population comprised
4625 type 2 diabetic patients diagnosed before 1st Jan.
1993 and still alive until 31 Dec. 1995 in Tayside, Scot-
land. Number of hospitalizations for each patient was
calculated using a record linkage database. Risk factors
age, gender and previous hospitalization for cardiovascu-
lar diseases were obtained from the databases. We com-
pared Poisson, two-part Poisson, Negative binomial (NB)
and two-part NB models. The two-part models include a
logistic regression model as the first part and the trun-
cated Poisson or NB models as the second part. The max-
imum likelihood procedure was used to fit the models.
The likelihood ratio test and the Akaikes Information
Criterion were used for model comparison. RESULTS:
The best model was the two-part NB model. The risk fac-
tors associated with at least one hospitalization were age
(log-OR  0.0245, S.E.  0.0026) and previous hospi-
talization for MI (log-OR  0.5960, S.E.  0.1137),
Stroke (log-OR  0.7181, S.E.  0.1915) and other car-
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diovascular diseases (log-OR  0.7488, S.E.  0.0912).
The overdispersion parameters for the NB model and the
two-part NB model were 0.3929 and 1.3796 respec-
tively, indicating the necessity of applying a two-part
model. CONCLUSION: Our data support the hypothesis
that there is individual heterogeneity for risk of hospital-
ization and a “healthy” sub-population of patients with
Type 2 diabetes. Consequently we recommend applica-
tion of two-part models that first predicts the risk of any
hospitalization for each individual in the population and
then predicts the likely number of hospitalizations sepa-
rately for high and low risk sub-populations.
DB2
AGGREGATION OF WILLINGNESS-TO-PAY 
MEASURED IN DECOMPOSED SCENARIOS
Klose T1, Zeitler HP2, Leidl R1
1Department of Health Economics, University of Ulm, Ulm, 
Germany; 2Department of General Medicine, University of 
Ulm, Ulm, Germany
OBJECTIVE: For cost-benefit analysis, health technolo-
gies with multiple effects should theoretically be valued
in a single scenario by a holistic willingness-to-pay (WTP)
measure. Recently, decomposed scenarios in which re-
spondents state their WTP for each individual effect were
used more often. Evidence can be found that the sum of
such decomposed WTPs overestimates the holistic WTP,
i.e. the holistic WTP is subadditive. No theoretically
founded and empirically validated aggregation function
for decomposed WTPs exists. Our aims were to derive
such an aggregation function and to test it empirically.
METHODS: Within an expected utility model, we identi-
fied risk aversion with respect to money and a positive
correlation of better health and marginal utility of money
as reasons for subadditivity. Under mutual utility inde-
pendence of health and money, we derived a theoretically
founded aggregation function covering these two im-
pacts. For an empirical application of this function, one
has to determine the utilities of the health states, of well-
defined states “rich&ill” and “poor&healthy”, and a
utility function over money—beside the decomposed
WTPs. In a contingent valuation study, we asked 92 pa-
tients with diabetes to state their WTP for reductions in
the risk of several diabetic complications in decomposed
and holistic scenarios. Utilities were measured by standard
gamble procedures. 46 patients (group 1) valued two com-
plications (diabetic retinopathy & neuropathy). The re-
maining 46 patients (group 2) valued also a third compli-
cation (diabetic foot). RESULTS: Subadditivity occurred
in both groups, but was not statistically significant. The
sum of decomposed WTPs overestimated holistic WTP by
8.3% in group 1 and 16% in group 2. Theoretically
founded aggregation underestimated holistic WTP by 2%
in group 1 and 1.2% in group 2. CONCLUSIONS: The
results of our pilot study suggest that the theoretically
founded aggregation function might overcome problems
of subadditivity, which can be economically relevant. Fur-
ther empirical testing of the approach is indicated.
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OBJECTIVE: To measure whether more rapid transition
toward insulin therapy in newly diagnosed Type II dia-
betic patients improves blood glucose control (BGC) and
reduces risk of diabetic related complications (DC).
METHODS: We used longitudinal data obtained from
IMS Mediplus UK to identify patients newly diagnosed
with Type II diabetes between November 1, 1993 and
October 31, 1994. Newly diagnosed was defined as no
prior diagnosis or use of anti-diabetic agents. Patient data
for five years included demography, laboratory values
(Hb1Ac), treatment, DC and comorbidities. Patients were
assigned to an initial treatment modality including diet
and exercise (DE), sulfonylureas (S), anti-hyperglycemics
(A), a combination (C), insulin (I), or insulin plus an oral
agent (IO). Each stepwise transition in treatment, Hb1Ac
readings and manifestations of DC were tracked for at
least five years. Generalized Estimating Equations (GEE)
estimated the expected reduction in Hb1Ac as patients
transitioned to insulin sooner while controlling for base-
line Hb1Ac and initial treatment assignment. Logistic re-
gression was used to estimate the change in risk of DC
associated with reductions in Hb1Ac and accelerated
transitioning toward insulin treatment. RESULTS: 2,137
patients were eligible for analysis. By initial treatment pa-
tients were allocated as follows: 1,894 (DE), 200 (S), 30
(A), 10 (C), 3 (I), and 0 (IO). Stepwise patients transitioned
toward insulin with 180 patients by year 5. A total of 49
patients (2.3%) had at least one DC after controlling for
baseline. Hb1Ac was reduced by 0.0037 (P  0.001) for
each day sooner the patient was transitioned toward insu-
lin therapy or a reduction of 1.0 in Hb1Ac (12.5%) can be
expected if transitioned within 270 days. Logistic results in-
dicated that transitioning toward insulin therapy by day
270 yields a reduction in risk of DC of 0.388% (P  0.01).
CONCLUSION: Sooner transitioning to insulin therapy
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OBJECTIVE: To measure the willingness to pay (WTP)
for a reduction in the number of micturitions and urinary
